Ncardia and BlueRock Therapeutics have entered an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.   “BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities,” said Stefan Braam, ...